1 Table of Contents 1 Table of Contents 2 1.1 List of Tables 3 1.2 List of Figures 3 2 Executive Summary 5 2.1 Strong Unmet need for Prevention of Chronic Rejection 5 2.2 Moderately-Sized by Highly Innovative Pipeline 5 2.3 Chemokines and Immune Surface Antigens Appear to Hold Promise as Novel Targets 5 3 The Case for Innovation 6 3.1 Growing Opportunities for Biologic Products 7 3.2 Diversification of Molecular Targets 7 3.3 Innovative First-in-Class Product Developments Remain Attractive 7 3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 8 3.5 Sustained Innovation 8 3.6 GBI Research Report Guidance 9 4 Clinical and Commercial Landscape 10 4.1 Disease Overview 10 4.2 Symptoms 11 4.2.1 Transplant Rejection 11 4.2.2 Graft-Versus-Host Disease 12 4.3 Diagnosis 12 4.4 Etiology and Pathophysiology 13 4.4.1 Major Histocompatibility Complex 13 4.4.2 Allogeneic Immune Response 13 4.4.3 Innate Immunity 15 4.4.4 The Role of Cytokines 15 4.4.5 Types of Rejection 15 4.5 Epidemiology and Prognosis 17 4.5.1 Transplant Rejection 17 4.5.2 Graft-Versus-Host Disease 18 4.6 Treatment Options 18 4.6.1 Antibody Therapies 19 4.6.2 Calcineurin Inhibitors 19 4.6.3 Anti-Proliferative Agents 19 4.6.4 mTOR Inhibitors 20 4.6.5 Corticosteroids 20 4.7 Overview of Marketed Products 21 4.8 Current Unmet Needs 23 5 Assessment of Pipeline Product Innovation 24 5.1 Pipeline by Stage of Development, Molecule Type and Molecular Target 24 5.2 First-in-Class Programs Targeting Novel Molecular Targets 28 6 Transplant Rejection Signaling Network, Disease Causation and Innovation Alignment 36 6.1 Complexity of Signaling Networks 36 6.2 Signaling Pathways and First-in-Class Molecular Target Integration 36 6.3 First-in-Class Matrix Assessment 36 7 First-in-Class Target and Pipeline Program Evaluation 39 7.1 Pipeline Programs Targeting C-X-C Chemokine Receptor Type 1 and C-X-C Chemokine Receptor Type 2 39 7.2 Pipeline Programs Targeting Tumor Necrosis Factor Receptor Superfamily Member 5 41 7.3 Pipeline Programs Targeting Stimulator of Interferon Genes Protein 43 7.4 Pipeline Programs Targeting Leukocyte Surface Antigen CD47 44 7.5 Pipeline Programs Targeting Tyrosine Protein Kinase SYK 46 7.6 Pipeline Programs Targeting Potassium Voltage Gated Channel Subfamily A Member 3 48 8 Strategic Consolidations 50 8.1 Industry-Wide First-in-Class Deals 50 8.2 Licensing Deals 52 8.2.1 Deals by Region, Year and Value 52 8.2.2 Deals by Stage of Development and Value 53 8.2.3 Deals by Molecule Type, Molecular Target and Value 54 8.2.4 List of Deals with Disclosed Deal Values 56 8.3 Co-development Deals 57 8.3.1 Deals by Region, Year and Value 57 8.3.2 Deals by Stage of Development and Value 59 8.3.3 Deals by Molecule Type, Molecular Target and Value 59 8.3.4 List of Deals with Disclosed Deal Values 61 8.4 List of First-in-Class Pipeline Products with and without Prior Deal Involvement 62 9 Appendix 64 9.1 Abbreviations 64 9.2 Disease List 64 9.3 References 65 9.4 Research Methodology 70 9.4.1 Data integrity 70 9.4.2 Innovative and meaningful analytical techniques and frameworks 70 9.4.3 Evidence based analysis and insight 70 9.5 Secondary Research 70 9.5.1 Market Analysis 70 9.5.2 Pipeline Analysis 70 9.5.3 Licensing and Co-development Deals 71 9.6 Contact Us 71 9.7 Disclaimer 72

1.1 List of Tables Table 1: Transplantation Therapeutics, Global, Organ-Specific Symptoms of Transplant Rejection, 2017 11 Table 2: Transplantation Therapeutics, Global, Organ-Specific Symptoms of Acute GVHD, 2017 12 Table 3: Transplantation Therapeutics, Global, Organ-Specific Symptoms of Acute GVHD, 2017 12 Table 4: Transplantation Therapeutics, Global, Key Features of C-X-C Chemokine Receptor Type 1, 2017 40 Table 5: Transplantation Therapeutics, Global, Key Features of C-X-C Chemokine Receptor Type 2, 2017 40 Table 6: Transplantation Therapeutics, Global, Pipeline Programs Targeting C-X-C Chemokine Receptor Type 1 and C-X-C Chemokine Receptor Type 2, 2017 41 Table 7: Transplantation Therapeutics, Global, Key Features of Tumor Necrosis Factor Receptor Superfamily Member 5, 2017 42 Table 8: Transplantation Therapeutics, Global, Pipeline Programs Targeting Tumor Necrosis Factor Receptor Superfamily Member 5, 2017 43 Table 9: Transplantation Therapeutics, Global, Key Features of Stimulator of Interferon Genes Protein, 2017 44 Table 10: Transplantation Therapeutics, Global, Pipeline Programs Targeting Stimulator of Interferon Genes Protein, 2017 44 Table 11: Transplantation Therapeutics Global, Key Features of Leukocyte Surface Antigen CD47, 2017 45 Table 12: Transplantation Therapeutics, Global, Pipeline Programs Targeting Leukocyte Surface Antigen CD47, 2017 46 Table 13: Transplantation Therapeutics, Global, Key Features of Tyrosine Protein Kinase SYK, 2017 47 Table 14: Transplantation Therapeutics, Global, Pipeline Programs Targeting Tyrosine Protein Kinase SYK, 2017 47 Table 15: Transplantation Therapeutics, Global, Key Features of Potassium Voltage Gated Channel Subfamily A Member 3, 2017 49 Table 16: Transplantation Therapeutics, Global, Pipeline Programs Targeting Potassium Voltage Gated Channel Subfamily A Member 3, 2017 49 1.2 List of Figures Figure 1: Transplantation Therapeutics, US, Innovation Trends in Product Approvals, 1987-2014 6 Figure 2: Transplantation Therapeutics, US, Sales Performance of First-in-Class and Non-First-in-Class Products Post Marketing Approval, 2006-2013 8 Figure 3: Transplantation Therapeutics, Global, Overview of Marketed Products, 2017 22 Figure 4: Transplantation Therapeutics, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2017 24 Figure 5: Transplantation Therapeutics, Global, Pipeline by Stage of Development and Molecule Type, 2017 25 Figure 6: Transplantation Therapeutics, Global, Key Indications by Stage of Development and Molecule Type, 2017 26 Figure 7: Transplantation Therapeutics, Global, Pipeline by Molecular Target, 2017 27 Figure 8: Transplantation Therapeutics, Global, Key Indications by Molecular Target, 2017 28 Figure 9: Transplantation Therapeutics, Global, Distribution of Pipeline First-in-Class and Non-First-in-Class Products by Stage of Development and Molecular Target, 2017 29 Figure 10: Transplantation Therapeutics, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Pipeline Products with a Disclosed Target by Stage of Development (%), 2017 29 Figure 11: Transplantation Therapeutics, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Pipeline Products by Molecular Target (%), 2017 30 Figure 12: Transplantation Therapeutics, Global, Ratio of First-in-Class Products to First-in-Class Targets by Stage of Development, 2017 30 Figure 13: Transplantation Therapeutics, Global, Ratio of First-in-Class Products to First-in-Class Targets by Molecular Target, 2017 31 Figure 14: Transplantation Therapeutics, Global, Pipeline Products, 2017 (Part 1) 31 Figure 15: Transplantation Therapeutics, Global, Pipeline Products, 2017 (Part 2) 32 Figure 16: Transplantation Therapeutics, Global, Pipeline Products, 2017 (Part 3) 33 Figure 17: Transplantation Therapeutics, Global, Pipeline Products, 2017 (Part 4) 34 Figure 18: Transplantation Therapeutics, Global, Pipeline Products, 2017 (Part 5) 35 Figure 19: Transplantation Therapeutics, Global, First-in-Class Matrix Assessment, 2017 38 Figure 20: Pharmaceutical Industry, Global, Licensing Deals by Stage of Development, 2006-2015 50 Figure 21: Pharmaceutical Industry, Global, Industry-Wide Licensing Deals by Deal Value, Upfront Payment Value, Stage of Development and First-in-Class Status ($m), 2006-2015 51 Figure 22: Transplantation Therapeutics, Global, Licensing Deals by Region, Value and Year, 2006-2017 53 Figure 23: Transplantation Therapeutics, Global, Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006-2017 54 Figure 24: Transplantation Therapeutics, Global, Number and Aggregate Deal Value of Licensing Deals by Molecule Type and Molecular Target, 2006-2017 55 Figure 25: Transplantation Therapeutics, Global, Licensing Deals with Disclosed Deal Values, 2006-2017 56 Figure 26: Transplantation Therapeutics, Global, Co-development Deals by Region, Value and Year, 2006-2017 58 Figure 27: Transplantation Therapeutics, Global, Co-development Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006-2017 59 Figure 28: Transplantation Therapeutics, Global, Number and Aggregate Deal Value of Co-development Deals by Molecule Type and Molecular Target, 2006-2017 60 Figure 29: Transplantation Therapeutics, Global, Co-development Deals with Disclosed Deal Values, 2006-2017 61 Figure 30: Transplantation Therapeutics, Global, First-in-class Programs in Active Development Without Recorded Prior Deal Involvement, 2017 (Part 1) 62 Figure 31: Transplantation Therapeutics, Global, First-in-class Programs in Active Development Without Recorded Prior Deal Involvement, 2017 (Part 2) 63